🇯🇵 Japan Country × Condition
solid tumor Clinical Trials in Japan
Active clinical trials for solid tumor with research sites in Japan. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2, Phase 1 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇯🇵 Japan
Active Trials in Japan (2)
NCT04300556 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Enrollment
182 pts
Country
🇯🇵 Japan
Eisai Inc.
View Trial → NCT05907980 Phase 1
Recruiting
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Enrollment
209 pts
Country
🇯🇵 Japan
Chugai Pharmaceutical
View Trial → Frequently Asked Questions
How many solid tumor clinical trials are active in Japan?
There are currently 2 active clinical trials for solid tumor with sites in Japan, of which 2 are actively recruiting patients.
How can I join a solid tumor clinical trial in Japan?
To join a solid tumor clinical trial in Japan, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Japan directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are solid tumor trials in Japan?
Active solid tumor trials in Japan span Phase 1, Phase 2, Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology